Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Nuvectis Pharma (NVCT) reported Q3 2025 results showing higher operating spending as clinical programs progressed and licensing costs increased. Cash and cash equivalents were $35.4 million as of September 30, 2025, compared with $18.5 million at year-end 2024. The company posted a Q3 net loss of $7.5 million and a nine‑month net loss of $19.1 million. A warrant term extension recorded as an $2.4 million effect increased the total net loss attributable to common shareholders in Q3.
Operating drivers: R&D expense rose to $5.8 million in Q3 (from $2.8 million) mainly due to a $2.0 million license fee for NXP900 and higher clinical costs; G&A was $2.0 million (from $1.5 million). Year‑to‑date, R&D reached $13.1 million and G&A $6.9 million. To fund operations, Nuvectis raised capital via equity: in February 2025 it sold 3,105,000 shares at $5.00 for $14.0 million net, and in Q3 it sold 1,707,309 shares under its ATM for $13.5 million gross ($13.1 million net). Management believes current cash funds planned operations for at least 12 months.
Pipeline: NXP900 advanced into Phase 1b in August 2025; a DDI study classified it as a weak CYP3A inhibitor. The company issued a final update for NXP800 in July and will not pursue further development in ovarian cancer while assessing other indications.
Nuvectis Pharma (NVCT) reported Q3 2025 results showing higher operating spending as clinical programs progressed and licensing costs increased. Cash and cash equivalents were $35.4 million as of September 30, 2025, compared with $18.5 million at year-end 2024. The company posted a Q3 net loss of $7.5 million and a nine‑month net loss of $19.1 million. A warrant term extension recorded as an $2.4 million effect increased the total net loss attributable to common shareholders in Q3.
Operating drivers: R&D expense rose to $5.8 million in Q3 (from $2.8 million) mainly due to a $2.0 million license fee for NXP900 and higher clinical costs; G&A was $2.0 million (from $1.5 million). Year‑to‑date, R&D reached $13.1 million and G&A $6.9 million. To fund operations, Nuvectis raised capital via equity: in February 2025 it sold 3,105,000 shares at $5.00 for $14.0 million net, and in Q3 it sold 1,707,309 shares under its ATM for $13.5 million gross ($13.1 million net). Management believes current cash funds planned operations for at least 12 months.
Pipeline: NXP900 advanced into Phase 1b in August 2025; a DDI study classified it as a weak CYP3A inhibitor. The company issued a final update for NXP800 in July and will not pursue further development in ovarian cancer while assessing other indications.
Nuvectis Pharma (NVCT) reported a Form 4 for director Juan Sanchez showing the acquisition of 30,000 shares of restricted common stock on 09/22/2025 at a stated price of $0. The award vests in equal annual installments over three years beginning on the first anniversary of the grant date, contingent on his continued service on the Board.
After the reported transaction, Dr. Sanchez beneficially owned 65,150 shares directly and 415 shares indirectly as custodian for his son.
Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025. The filing lists beneficial ownership of 35,150 shares of common stock (direct), plus 295 shares (indirect) and 120 shares (indirect) held as custodian for a son. Table II shows no derivative securities. The form was signed by Juan Sanchez on 10/31/2025.
Nuvectis Pharma (NVCT) reported insider purchases by director Charles Mosseri‑Marlio. He indirectly acquired common stock across three open‑market transactions: 46,900 shares at $6.06 on October 23, 35,034 shares at $6.15 on October 24, and 72,836 shares at $6.28 on October 27.
Following these trades, he beneficially owned 3,136,576 shares, held indirectly through Emerald Hill Ventures SARL SPF, of which he is the beneficial owner.
Nuvectis Pharma, Inc. filed a current report to disclose that its Board of Directors appointed Juan Sanchez, MD as a new director on September 22, 2025. He will serve on the Board until his term expires at the 2026 annual meeting of stockholders, when he is expected to stand for election by stockholders.
The company states that Dr. Sanchez has no arrangements or understandings with any other person related to his appointment, no family relationships with existing directors or executive officers, and no material interests in related-party transactions as described under Item 404(a) of Regulation S-K. Nuvectis announced his appointment in a press release dated September 25, 2025, which is included as an exhibit to the report.
Form 4 Overview: On 06/20/2025, Charles Mosseri-Marlio, a 10% owner of Nuvectis Pharma, Inc. (NVCT), filed a Form 4 disclosing an open-market purchase of 5,603 shares of the company’s common stock at a price of $7.99 per share. The transaction was executed indirectly through Emerald Hill Ventures SARL SPF, an entity Mosseri-Marlio beneficially owns.
Following the purchase, the insider’s aggregate ownership rose to 2,981,806 shares held indirectly and 109,321 shares held directly. The filing lists transaction code "P," signifying a standard open-market purchase. No sales, derivative security activity, or 10b5-1 plan indications were reported.
The additional shares represent less than 0.2% of Mosseri-Marlio’s total reported holdings but still reflect continued alignment with public shareholders. The filing contains no operational updates or financial metrics beyond the share purchase details.
Key take-away: Nuvectis Pharma, Inc. (NVCT) filed a Form 4 showing that 10% owner Charles Mosseri-Marlio, via Emerald Hill Ventures SARL SPF, bought 33,442 common shares in two open-market transactions on 17-18 Jun 2025.
- Prices: weighted-average $8.11 on 17 Jun for 5,399 shares and $8.05 (range $7.91-$8.11) on 18 Jun for 28,043 shares.
- Post-purchase holdings: 2,976,203 shares held indirectly, up from 2,942,761.
- Transaction code “P” confirms open-market purchases; no 10b5-1 plan indicated.
- No derivative securities or sales reported; filing does not include earnings or operational metrics.
The estimated cash outlay is roughly $270k; insider accumulation at market prices often signals management’s confidence and can be viewed as a bullish indicator by investors. Because the investor already owns more than 10% of NVCT, the additional purchase marginally increases an already significant stake and reinforces alignment with minority shareholders.